CSPC PHARMA(01093.HK): Receives USD10‑Million Milestone Payment from AstraZeneca
NewTimeSpace News: CSPC Pharma (01093.HK) released a voluntary announcement on 5 August 2026. The Group has received a USD10‑million milestone payment from AstraZeneca for exercising the licensing option for one pre‑clinical candidate compound (PCC) project in accordance with the agreement terms, which indicates that relevant R&D work under the agreement is advancing steadily as planned.
The two parties entered into the strategic R&D cooperation agreement on 13 June 2025. The Group agreed to discover PCCs with multi‑disease therapeutic potential for multiple targets selected by AstraZeneca, including one pre‑clinical small‑molecule oral therapy for immune diseases.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC PHARMA (01093.HK): Phase II Trial of SYH2069 Injection for Adult Type 2 Diabetes Commences at First Site in China
- CSPC PHARMA (01093.HK): SYS6010 Included in China's Breakthrough Therapy Designation List for Driver-Gene-Negative Non-Squamous NSCLC
- CSPC PHARMA (01093.HK): Phase I/II Data of SYS6010 Combined with Enlangsuba Monoclonal Antibody in Previously Untreated Driver-Gene-Negative Advanced NSCLC Presented as Oral Presentation at 2026 WCLC
- CSPC PHARMA (01093.HK): SYH9087, China's First Subcutaneous Rotigotine Long-acting Product, Cleared for Clinical Trials
- CSPC PHARMA (01093.HK): SYH9102, World's First Ready-to-use Goserelin Extended-release Injection, Cleared for Clinical Trials in China
